Beyond the Legacy Hub: Why Speed Kills Ghost Prescriptions

Traditional hub and patient support services often rely on disconnected, manual processes that slow everything down. In a market where getting patients started on therapy is everything, time to first fill has become the metric that separates living prescriptions from dead ones.

‍

Speed drives revenue. Legacy hubs can take days or weeks to navigate benefits and approvals—plenty of time for prescriptions to go cold. An intelligent direct-to-patient platform integrates pharmacy, technology, and patient support into one automated flow. Deloitte’s latest analysis on commercial biopharma confirms what we're seeing: DTP models deliver significantly higher conversion and persistence rates than traditional channels.

‍

Solving the Gross-to-Net Problem

For years, manufacturers have watched middlemen including PBMs and wholesalers dictate gross-to-net (GTN) economics, forcing brands into overlapping rebates and 340B pressures.

‍

Direct-to-patient models let manufacturers take back control of the economics. By cutting out layers of traditional distribution, you can direct resources where they actually matter: to patients. Instead of waiting weeks for backward-looking data, a digital-first platform gives you visibility in real time. This matters especially now, as 2026 market access trends from Pharmacy Times show a fundamental shift toward multimodal payer models where owning your data is the only way to protect your margins.